anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Cobalt-chromium-molybdenum (CoCrMo) and titanium alloys have been used for orthopaedic implants for decades. However, recent evidence has shown that inflammatory cell-induced corrosion (ICIC) can damage these metal alloys. This study aimed to investigate the mechanisms of ICIC by coculturing macrophages with lymphocytes. We hypothesized that macrophages would be able to alter the surface oxide layer of CoCrMo and titanium alloy (Ti6Al4V) disks, with greater oxide layer damage occurring in groups with a coculture compared to a macrophage monoculture and in groups with inflammatory activators compared to nonactivated groups.
METHODS: Murine macrophages were cultured on American Society for Testing and Materials F1537 CoCrMo and F136 Ti6Al4V disks for 30 days and activated with interferon gamma and lipopolysaccharide. Interferon gamma and lipopolysaccharide were added to the culture medium to simulate local inflammation. Macrophages were either cultured alone or in a coculture with T helper lymphocytes. After the 30-day experiment, scanning electron microscopy was used to examine the disk surfaces, and oxide levels were found using energy dispersive x-ray spectroscopy.
RESULTS: Pitting features consistent with previous reports of ICIC were found on disks cultured with cells. Both CoCrMo and Ti6Al4V disks had significantly lower oxide levels in all groups with cells compared to control groups with no cells (P < .01). Additionally, CoCrMo disks had significantly lower oxide levels when cultured with activated macrophages and lymphocytes compared to nonactivated macrophages alone (P < .001), activated macrophages alone (P < .01), and nonactivated macrophages and lymphocytes (P < .05). No differences in the oxide levels were found among the Ti6Al4V groups.
CONCLUSIONS: This study demonstrates the ability of macrophages to alter the surface chemistry of commonly used orthopaedic alloys. We found that the addition of lymphocytes and a simulated local inflammatory response may contribute to the ICIC of CoCrMo implants.
Various genetic and epigenetic changes associated with genomic instability (GI), including DNA damage repair defects, chromosomal instability, and mitochondrial GI, contribute to development and progression of cancer. These alterations not only result in DNA leakage into the cytoplasm, either directly or through micronuclei, but also trigger downstream inflammatory signals, such as the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway. Apart from directly inducing DNA damage to eliminate cancer cells, radiotherapy (RT) exerts its antitumor effects through intracellular DNA damage sensing mechanisms, leading to the activation of downstream inflammatory signaling pathways. This not only enables local tumor control but also reshapes the immune microenvironment, triggering systemic immune responses. The combination of RT and immunotherapy has emerged as a promising approach to increase the probability of abscopal effects, where distant tumors respond to treatment due to the systemic immunomodulatory effects. This review emphasizes the importance of GI in cancer biology and elucidates the mechanisms by which RT induces GI remodeling of the immune microenvironment. By elucidating the mechanisms of GI and RT-induced immune responses, we aim to emphasize the crucial importance of this approach in modern oncology. Understanding the impact of GI on tumor biological behavior and therapeutic response, as well as the possibility of activating systemic anti-tumor immunity through RT, will pave the way for the development of new treatment strategies and improve prognosis for patients.
Background: Atrial fibrillation (AFib) detection via mobile ECG devices is promising, but algorithms often struggle to generalize across diverse datasets and platforms, limiting their real-world applicability. Objective: This study aims to develop a robust, generalizable AFib detection approach for mobile ECG devices using crowdsourced algorithms. Methods: We developed a voting algorithm using random forest, integrating six open-source AFib detection algorithms from the PhysioNet Challenge. The algorithm was trained on an AliveCor dataset and tested on two disjoint AliveCor datasets and one Apple Watch dataset. Results: The voting algorithm outperformed the base algorithms across all metrics: the average of sensitivity (0.884), specificity (0.988), PPV (0.917), NPV (0.985), and F1-score (0.943) on all datasets. It also demonstrated the least variability among datasets, signifying its highest robustness and effectiveness in diverse data environments. Moreover, it surpassed Apple's algorithm on all metrics and showed higher specificity but lower sensitivity than AliveCor's Kardia algorithm. Conclusions: This study demonstrates the potential of crowdsourced, multi-algorithmic strategies in enhancing AFib detection. Our approach shows robust cross-platform performance, addressing key generalization challenges in AI-enabled cardiac monitoring and underlining the potential for collaborative algorithms in wearable monitoring devices.
PURPOSE:To provide the title compsn. which is lowly toxic and does not remain silica on the skin after use, consisting of specific silicone oil and a sucrose fatty acid ester. CONSTITUTION:100pts.wt. silicone oil (A) composed of 20-100wt.% methylphenylpolysiloxane having a viscosity of 4-1,000cst at 25 deg.C and at least one phenyl group, represented by formula I (wherein R is methyl or phenyl; lis 2-3), 0-50wt.% cyclic dimethlpolysiloxane of formula II (wherein m is 3-6) and 0-50wt.% dimethylpolysiloxane of formula III (wherein Q is H or trimethylsilyl; n is 1-650) is blended with 5-50pts.wt. sucrose fatty acid ester (B). The blend is mixed at 50-100 deg.C.
In this paper, we investigated the psychometric properties of the Child Communication Checklist-Revised (CCC-R) for the first time with an English-speaking sample. We used a confirmatory application of exploratory structural equation modeling (ESEM) to re-evaluate the CCC-R's psychometric properties. We found strong support for its use as an assessment for pragmatic and structural language. Our second main aim was to explore associations between pragmatic and structural language and restricted and repetitive behaviors (RRBs), two hallmark characteristics of autism. We used the CCC-R and Repetitive Behavior Questionnaire (RBQ-2) to investigate these associations in a diverse non-clinical sample of children, taking a transdiagnostic approach. We intentionally excluded autism and other neurodevelopmental diagnoses to test, (1) the CCC-R in a broad sample and (2) the association between pragmatic language and RRB in children not already selected for that association. The sample comprised two groups of children, one was community sampled (n = 123) and the other (n = 143) included children with non-specific behavioral, emotional and/or cognitive difficulties referred to an assessment unit by schools. We found clear associations between pragmatic language difficulties and RRBs in both groups. Regression analysis showed that pragmatic language was the only significant contributor to RRBs even after Grammatical-Semantic score, age, sex, and socioeconomic status were controlled. The pattern was the same for both recruitment groups. However, the effects were stronger for the school-referred group which also had more pragmatic difficulties, grammatical-semantic difficulties and RRBs. A robust link between pragmatic language and RRBs, established in autism, has continuity across the broader non-clinical population.
The IT-MSC-NP treatments and all clinical assessments will take place at a single center (Tisch MSRCNY). Study subjects will be assigned to blocks stratified by baseline EDSS score (3.0-4.0, 4.5-5.5, 6.0, and 6.5) and disease subtype (SPMS or PPMS). Study subjects are randomized in an equal fashion (1:1) to study treatment and placebo at initial randomization. Subjects in each block will be randomized into placebo or treatment group. In the second year, treated subjects will cross over to the placebo group and placebo subjects will cross over to the treated group.

The total study duration will be 3 years upon enrollment. Each study subject will be required to attend up to 18 study visits, to include 1 screening visit, 1 bone marrow visit, 1 baseline visit, followed by study visits every 2 months during the treatment period of two years (12 treatment/LP procedure visits and 2 outcome visits), and an additional follow-up visit at the end of year 3.
Roughly described, historical healthcare records are linked by patient and searched for instances of an episode of healthcare interaction, anchored by a predefined anchor event. Meaningful input and output variables applicable to the episode are identified. Machine learned models are developed which predict the effect that input process variables have on the output variables, and these models are written to a process change exploration data store. Then, through a GUI, a user interactively explores various schedules for changing physical healthcare processes, and the system visually forecasts resulting changes in total cost of an EHI, Planned process changes are implemented and the system visually tracks actual progress both of input process variable implementation and output variable changes. The user can use this information to modify implementation schedules for input process changes. The system can also predict total cost of a specific ongoing EHI long before actual financial claims data are available.
The invention discloses a targeting PD-L1/HSA/CCL5 trispecific nano antibody and a derivative and application thereof. The amino acid sequence of the targeting PD-L1/HSA/CCL5 trispecific nanometer antibody provided by the invention is selected from any one of amino acid sequences shown in SEQ ID NO.1-SEQ ID NO. 8. The invention also provides a derivative obtained by conjugating the nano antibody with a functional molecule. The nano antibody provided by the invention has extremely strong binding activity and affinity to PD-L1 and CCL 5. The invention further provides application of the PD-L1/HSA/CCL5 targeted trispecific nano-antibody and derivatives thereof in preparing medicaments or reagents for treating or diagnosing tumors related to C-FOXP3 elevation.
PURPOSE: To obtain excellent heat ray shielding properties by using an additive element selected from among group IIIB and IVB metallic elements of the periodic table and Zn as metallic components and a coprecipitated substance of a metallic oxide manifesting the ZnO crystallinity at a specific ZnO content as a constituent component. CONSTITUTION: A Zn source such as ZnO powder and a metallic element source selected from among group IIIB and IV metallic elements of the periodic table are added to a mixed solvent of a monocarboxylic acid having <=200 deg.C boiling point such as acetic acid with water. The temperature of the mixture solution is increased under stirring to dissolve both Zn and the metallic element sources to prepare a solution containing a metal such as Zn. The resultant solution containing the metal is then dropped into a heated solvent such as 2-butoxyethanol and the obtained mixture is heated to about 100-300 deg.C. An additive such as lauric acid is then added thereto.  The prepared mixture is stirred to provide ZnO-based primary fine particles, having 0.001-0.1μm average particle diameter, comprising a coprecipitated metallic oxide substance containing 80-99.1% Zn and 0.1-20% other metals expressed in terms of the ratio of number of atoms and capable of manifesting the ZnO crystallinity. Furthermore, a lactic acid source is added to the solution containing the metal and the resultant mixture solution is heat-treated at >=100 deg.C to afford secondary fine particles having 0.001-10μm average particle diameter.
<P>PROBLEM TO BE SOLVED: To provide a novel anticancer agent which is difficult to be released from a cancer cell and suitable for topical treatment against a cancer cell.  <P>SOLUTION: The anticancer agent comprises a rotaxane compound represented by chemical formula (I) as an effective ingredient. The rotaxane compound is composed of two parts including a rod-like part having relatively large molecules bonded at both ends thereof and a circular part (crown ether) through which the rod-like part is pierced. The relatively large molecules are bonded to both ends of the rod-shaped part, and the molecules act as a stopper, so that the circular part cannot release from the rod-shaped part. The two parts are bonded not through covalent bond. Therefore, the shape of the molecules readily changes, and the incorporation thereof through a receptor is relatively difficult, however, introduction thereof into a cancer cell can suppress proliferation of the cancer cell.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Various embodiments for providing remote delivery and monitoring of health care are provided. In one embodiment, an apparatus for providing unmanned medical care in remote areas to a patient is provided. A container is adapted for transport using a standardized shipping mechanism. The container is adapted to provide remote delivery of health care. In an additional embodiment, a portable apparatus for dermatological monitoring is provided. An imaging device is integrated into a housing. The imaging device is adapted to obtain a digital, high-resolution image of a patient. In still another embodiment, a portable apparatus for orthopedic monitoring of a patient is provided. A housing is adapted for one of positioning adjacent to and positioning within an orthopedic cast. A diagnostic biomedical device integrated into the housing. The diagnostic biomedical device is adapted for obtaining an orthopedic image of a portion of the patient treated with the orthopedic cast.
Subjects aged 8-15 years at enrollment with new-onset type 1 diabetes mellitus (T1DM) received Aralast NP 45 mg/kg by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants underwent a minimum 3-week washout period. After the washout period, each participant proceeded to a high dose of Aralast NP 90 mg/kg by IV infusion for the next 6 weeks, for a total of 12 infusions.
<P>PROBLEM TO BE SOLVED: To clearly, uniformly and beautifully finish the surface of a cosmetic over the whole while suppressing the bad effects on quality.  <P>SOLUTION: Press treatment is applied to a cosmetic mixture 1 filled in a cosmetic dish 2. As a result, the surface of the cosmetic mixture 1 is protruded from the upper edge of the cosmetic dish 2. The surface of the cosmetic mixture 1 is horizontally cut by a cutter 4. The press treatment is applied again to the cosmetic mixture 1 the surface of which has been cut.  <P>COPYRIGHT: (C)2010,JPO&INPIT
According to a working group of World Health Organization, arsenicosis is a chronic health condition arising from prolonged ingestion (not less than six months) of arsenic above a safe level, usually manifested by characteristic and most diagnostic skin lesions, like- melanosis, leucomelanosis and keratosis, with or without involvement of internal organs. Arsenical keratosis usually appears on palm of the hand and plantar aspect of the feet and may also develop on the dorsum of the extremities and trunk. It had been found in certain studies that there is an alteration of normal skin flora in patients with arsenical keratosis. The relationship between such altered skin flora and development of keratosis in arsenicosis is not established or explored. Treatment of all types of keratosis is difficult. The most common therapeutic option leads to short-term improvement and is frequently associated with various adverse effects. Treatment tends to be symptomatic and includes topical keratolytic, orally administered antioxidant vitamins and minerals, or reconstructive surgery with total excision of the keratotic skin followed by grafting. There is no such study where effects of antimicrobials have been evaluated as the treatment of arsenical keratosis. So the present study is designed to see the effects of antimicrobials on the altered skin flora (Enterobacter and Aspergillus) in patients with palmar arsenical keratosis. The present study will be a clinical trial. The study will take place at the Department of Pharmacology, Department of Microbiology and Immunology of Bangabandhu Sheikh Mujib Medical University and at Laksham Upazilla of Comilla District from September 2017 to February 2019. After including participants as per selection criteria, written informed consent will be taken from all of them. Then water, nail, skin swab and scrapping samples will be collected and analyzed in the laboratory. After doing culture sensitivity, antimicrobials will be given to the patients. The duration of treatment will be decided upon sensitive drugs. Keratotic nodular size will be measured of each patient to draw a conclusion about the effect of antimicrobials in patients with palmar arsenical keratosis. As it had been found in previous studies conducted at the Department of Pharmacology of Bangabandhu Sheikh Mujib Medical University that both skin bacterial and fungal flora were altered in patients with arsenical keratosis, this study will be done to establish the relationship between such alteration and arsenical keratosis by exploring the effects of antimicrobials as a treatment of keratosis.
BACKGROUND: Traboulsi syndrome is a sporadic autosomal recessive disorder. Very few cases reported and no surgical treatment has been described.
PURPOSE: The purpose of the study was to describe the surgical treatment of a case of Traboulsi syndrome with intercalary staphyloma.
SYNOPSIS: Traboulsi syndrome[1-3] is a type of spontaneous filtering bleb. The case was of a 31-year-old lady with a flat anterior chamber and large intercalary staphyloma, with a subluxated clear lens. Liberal peritomy was done. The staphyloma was cut and the displaced lens was delivered through it. It was closed with 7-0 vicryl continuous suture. A cross-linked cornea was used after removing the Descemet membrane. It was modified to match the crescentic shape of the limbus by using 11 and 6 mm trephine. Two wedge-shaped defects were created and tissue was excised between them, which were then sutured to increase the arc radius. A peripheral flange at the corneal edge was created. A pocket was created in the host cornea to accommodate the donor corneal flange. The donor cornea was tucked in and the graft was sutured. The sclera was used to suture another side prophylactically, making a 360-degree encirclage. The patient got ambulatory vision postsurgery. The use of the cornea as biological encirclage has not been described previously.
HIGHLIGHTS: Using a cross-linked cornea. Creating wedge-shaped defects in crescentic corneal graft to increase arc radius. Use of cornea as encirclage.Link of video:https://youtu.be/T3b5rkvFmlc.
A method of permanent hair removal which uses a high energy light source projected at the skin to cause death of the hair follicle by photothermolysis. The process uses either incoherent or coherent light energy. Additional melanin is added to the skin by a process which delivers the melanin to the region of the hair follicle thereby enhancing that area as a light absorbing target. Collateral damage to the surrounding skin tissue is minimized. The delivery process uses liposomes selected particularly to encapsulate and carry melanin to the target region. The invention also encompasses a general method of deleterious tissue destruction by selective introduction of melanin and subsequent photothermolysis.
This was a randomised controlled trial of the effect over 12 months of a one-to-one educational package designed to improve foot care behaviour in a group of patients at the highest risk of new foot disease: those with a recently healed ulcer. The primary outcome was the incidence of new ulceration at 12 months. Secondary outcomes included self-reported footcare behaviour, new ulceration at 6 months, amputation (major or minor) at 12 and 6 months, and measures of well-being (SF36; Diabetic Foot Ulcer Scale, DFS short-form). The educational intervention was based on the content of the International Consensus on the Diabetic Foot, 2003, was modified following discussion with a focus group of former ulcer sufferers, and included graphic images of different forms of foot disease. Although structured, the information was targeted in discussion to the individual's circumstances, and was delivered one-to-one in the patient's own home by a single health care professional. It was reinforced after one month by a semi-structured phone conversation with the same educator. Outcomes were determined by postal questionnaire, backed up with reminders and phone calls when necessary, as well questionnaires sent to GP staff and by searching hospital records. Foot care behaviour was assessed at 12 months using a newly devised and validated measure of footcare function (NAFF) which was also delivered by post. All outcomes were assessed by researchers blind to allocation group. Mean age was 64.9 (SD 10.9) years, and there were no differences between groups at baseline in terms of demographics, diabetes type and complications. The incidence (%) of new ulcers at 6 and 12 months was 26 (30%) and 36 (41%) in the intervention group and 18 (21%) and 35 (41%) in the controls, RR 0.997 (CI 0.776-1.280). There were no differences in any of the other outcome measures although the intervention group reported a higher score in recommended foot care behaviour when compared with controls (42.0 versus 38.7, p=0.03).
Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria. Subjects were randomized to the Deferred Treatment group are observed for 6 months. Upon completion of the observation follow-up, subjects can opt to have VisAbility micro inserts surgically implanted in the eye(s) and become part of the overall study experimental group.
The invention provides a fusion protein, which sequentially comprises the following components from an N end to a C end: SEC2 or a mutant thereof, a connecting short peptide and iRGD, wherein the mutation comprises deletion, insertion and/or substitution of 1-5 amino acids, the amino acid sequence of SEC2 is shown as SEQ ID NO. 31, the amino acid sequence of the connecting short peptide is shown as SEQ ID NO. 29, and the amino acid sequence of iRGD is shown as SEQ ID NO. 30. The invention also provides a preparation method and application of the fusion protein. The targeting fusion protein can be specifically targeted and infiltrated into a tumor tissue microenvironment, so that the tumor specificity and vascular permeability of the superantigen are greatly improved, and the killing efficiency on the tumor is improved, so that the survival capability of a patient can be effectively improved when the targeting fusion protein is used for treating the patient, and the targeting fusion protein has a good clinical application value.
PURPOSE: To obtain A-76202M as a new compound having inhibiting activity against α-glycosidase which exists in endoplasmic reticulum and useful as an anti-AIDS agent and antitumor agent by culturing A-76202M producing bacterium belonging to the genus Rhodococcus and then collecting the product. CONSTITUTION: This new compound is expressed by the formula and is white powder and soluble in dimethyl sulfoxide and water and slightly soluble in acetone and has the molecular formula C25 H26 O13 (measured by high resolution mass spectrum) and a molecular weight of 534 (measured by FAB-MS spectrum) and exhibits inhibiting activity against α-glycosidase which exists in endoplasmic reticulum, and is useful as an anti-AIDS agent, antitumor agent, etc. The new compound A-76202M is obtained by culturing A-76202M-producing bacterium belonging to the genus Rhodococcus [e.g. Rhodococcus sp. SANK61694 strain (FERM BP-4751), etc.] in a culture medium and collecting the product from the culture products.